Evidence map›Paper›PMID 32712720›Full record

ArticleClinical and experimental medicine2020

Clinical significance of serum miR-768-3p in HBV-related hepatocellular carcinoma and its potential mechanism.

Chunyu Cao, Changjiang Wang

Abstract read
PubMed Publisher
In one paragraph

Article in Clinical and experimental medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.6field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 10 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Chunyu CaoDepartment of Infectious Diseases, Caoxian People's Hospital, Heze, 274400, Shandong, China.
Changjiang WangDepartment of Gastroenterology, Caoxian People's Hospital, No. 1, Fuminda Road, Heze, 274400, Shandong Province, China. changjiangwang01@163.com.ORCID http://orcid.org/0000-0003-4231-2320
Cixian People's Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The purpose of this study was to reveal the clinical diagnostic and prognostic value of miR-768-3p in HBV-related HCC and to investigate its effect on the biological function of HCC. Quantitative real-time polymerase chain reaction was used to detect the expression level of miR-768-3p in subjects' serum. The receiver operating characteristics curve (ROC) evaluated the diagnostic value of miR-768-3p in patients. A Chi-square test was used to analyze the relationship between miR-768-3p and clinical data of patients. Kaplan-Meier survival and Cox regression analysis assessed the prognostic value of miR-768-3p in HCC. Finally, CCK-8 and Transwell assays were used to demonstrate the effect of miR-768-3p on HBV-related HCC function. Serum miR-768-3p was significantly lower in HCC patients than in healthy controls and chronic hepatitis B (CHB) patients. ROC curve suggested that serum miR-768-3p has an important diagnostic value for HBV-related HCC and can significantly differentiate HCC patients from healthy controls, and it can also diagnose HCC patients from CHB patients. Cox analysis confirmed that miR-768-3p was an independent risk factor. Low expression of miR-768-3p was associated with Tumor, Node, Metastasis stage, Barcelona Clinic Liver Cancer stage, and poor prognosis in HCC patients. Finally, cell function experiments confirmed that high expression of miR-768-3p could inhibit cell proliferation, migration, and invasion. All experiments confirmed that miR-768-3p can inhibit the proliferation, migration, and invasion of HBV-related HCC cells, and the low expression of miR-768-3p can be used as a potential diagnostic and prognostic biomarker for HBV-related HCC.

Indexed as

Biomarkers, TumorCarcinoma, HepatocellularCase-Control StudiesCell Line, TumorCell MovementCell ProliferationFemaleGene Expression Regulation, NeoplasticHepatitis B, ChronicHumansKaplan-Meier EstimateLiver NeoplasmsMaleMicroRNAsMiddle AgedPrognosisBiomarkers, TumorMicroRNAsMIRN768 microRNA, humanDiagnosticHepatitis B virusHepatocellular carcinomamiR-768-3pPrognostic

Identifiers

PMID32712720
OpenAlexW3045061085

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.